Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gottlieb

Showing results (221-230 of 609) with videos related to

Pageof 61
Sort By:
The British Journal of Dermatology|April 1, 2008
Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasisC Leonardi, A Menter, T Hamilton, et al.
Journal of the American Academy of Dermatology|July 27, 2025
Healthcare resource utilization and economic burden in generalized pustular psoriasis (GPP) among U.S. adults: A large claims database analysisMark Lebwohl, Bhargav Lakshminarasimhan, Layla Lavasani, et al.
Jac-Antimicrobial Resistance|January 5, 2023
The impact of COVID-19 on multidrug-resistant organisms causing healthcare-associated infections: a narrative reviewLucy S Witt, Jessica R Howard-Anderson, Jesse T Jacob, et al.
Pharmacology Research & Perspectives|June 4, 2015
Renal responses produced by microinjection of the kappa opioid receptor agonist, U50-488H, into sites within the rat lamina terminalisCynthia Franklin, Lourdes Fortepiani, Tin Nguyen, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
Report of the Skin Research Workgroups from the GRAPPA 2019 Annual MeetingLourdes M Perez-Chada, Joseph F Merola, April W Armstrong, et al.
Clinical Rheumatology|October 13, 2018
Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trialJ A Walsh, A B Gottlieb, B Hoepken, et al.
The Journal of Rheumatology|August 1, 2024
GRAPPA Point-Counterpoint: Should Biologics Be Used for Mild Psoriasis?Gretchen D Ball, Hassan Hamade, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|October 18, 2023
A clinical review of structural damage in psoriatic arthritis for dermatologists: From pathogenesis to ongoing controversiesJoseph F Merola, Soumya D Chakravarty, Olivia Choi, et al.
Journal of Drugs in Dermatology : JDD|May 12, 2016
Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque PsoriasisBrooke E Rothstein, Brianna McQuade, Jacqueline E Greb, et al.
The Journal of Rheumatology|March 3, 2011
Summary of minutes of the GRAPPA meeting adjacent to the American Academy of Dermatology 67th Annual MeetingWolf-Henning Boehncke, Alice B Gottlieb, Gerald G Krueger, et al.
Pageof 61

Showing results (221-230 of 609) with videos related to

Sort By:
Pageof 61
The British Journal of Dermatology|April 1, 2008
Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasisC Leonardi, A Menter, T Hamilton, et al.
Journal of the American Academy of Dermatology|July 27, 2025
Healthcare resource utilization and economic burden in generalized pustular psoriasis (GPP) among U.S. adults: A large claims database analysisMark Lebwohl, Bhargav Lakshminarasimhan, Layla Lavasani, et al.
Jac-Antimicrobial Resistance|January 5, 2023
The impact of COVID-19 on multidrug-resistant organisms causing healthcare-associated infections: a narrative reviewLucy S Witt, Jessica R Howard-Anderson, Jesse T Jacob, et al.
Pharmacology Research & Perspectives|June 4, 2015
Renal responses produced by microinjection of the kappa opioid receptor agonist, U50-488H, into sites within the rat lamina terminalisCynthia Franklin, Lourdes Fortepiani, Tin Nguyen, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
Report of the Skin Research Workgroups from the GRAPPA 2019 Annual MeetingLourdes M Perez-Chada, Joseph F Merola, April W Armstrong, et al.
Clinical Rheumatology|October 13, 2018
Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trialJ A Walsh, A B Gottlieb, B Hoepken, et al.
The Journal of Rheumatology|August 1, 2024
GRAPPA Point-Counterpoint: Should Biologics Be Used for Mild Psoriasis?Gretchen D Ball, Hassan Hamade, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|October 18, 2023
A clinical review of structural damage in psoriatic arthritis for dermatologists: From pathogenesis to ongoing controversiesJoseph F Merola, Soumya D Chakravarty, Olivia Choi, et al.
Journal of Drugs in Dermatology : JDD|May 12, 2016
Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque PsoriasisBrooke E Rothstein, Brianna McQuade, Jacqueline E Greb, et al.
The Journal of Rheumatology|March 3, 2011
Summary of minutes of the GRAPPA meeting adjacent to the American Academy of Dermatology 67th Annual MeetingWolf-Henning Boehncke, Alice B Gottlieb, Gerald G Krueger, et al.
Pageof 61